Table 1.
Variables selected by consensus (≥80%) during second round of the Delphi survey
CAPS |
||||||
---|---|---|---|---|---|---|
Variables | FMF (%) | TRAPS (%) | MKD (%) | FCAS (%) | MWS (%) | NOMID (%) |
Fatigue | 82 | 81 | 87 | 87 | 82 | |
Number of days of illness in the past 3 months | 94 | 88 | 100 | 93 | 87 | 82 |
Intensity of attacks | 89 | 81 | ||||
Arthritis | 100 | |||||
Arthralgia | 87 | 80 | 87 | |||
Measure of joint damage | 94 | |||||
Presence absence of skin rash | 94 | 81 | 82 | 100 | 100 | 88 |
Intensity of skin rash | 93 | 87 | 88 | |||
Frequency of skin rash | 87 | 80 | ||||
Number of days with skin rash in a month | 93 | 93 | 82 | |||
Chest symptoms | 94 | |||||
Muscle symptoms | 82 | |||||
Gastrointestinal symptoms | 100 | |||||
Painful lymphnodes | 94 | |||||
Hearing loss | 93 | 82 | ||||
Eye symptoms | 82 | |||||
Headaches | 82 | |||||
Brain MRI | 82 | |||||
Cognitive function test | 94 | |||||
Funduscopy | 88 | |||||
Limitation of daily activity | 89 | 87 | 87 | 80 | 81 | |
Days of school /work loss | 83 | 81 | ||||
Global DAS physician | 83 | 81 | 88 | |||
Global DAS patient | 82 | |||||
ESR | 83 |
New variables/items suggested by experts after the first round are shown in italics.
CAPS, cryopyrin-associated periodic syndromes; CINCA/NOMID, chronic infantile neurological, cutaneous, articular/neonatal onset multisystem inflammatory disease; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; FCAS, familial cold autoinflammatory syndrome; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; TRAPS, TNF receptor-1-associated periodic syndrome.